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ABSTRACT
Objectives: Previous studies of a fixed combination including cotrimoxazole, rifampicin, and
isoniazid (Cotrifazid) showed efficacy against resistant strains of Plasmodium falciparum in
animal models and in small-scale human studies. We conducted a multicentric noninferiority
trial to assess the safety and efficacy of Cotrifazid against drug-resistant malaria in Papua New
Guinea.
Design: The trial design was open-label, block-randomised, comparative, and multicentric.
Setting: The trial was conducted in four primary care health facilities, two in urban and two in
rural areas of Madang and East Sepik Province, Papua New Guinea.
Participants: Patients of all ages with recurrent uncomplicated malaria were included.
Interventions: Patients were randomly assigned to receive Cotrifazid, mefloquine, or the
standard treatment of quinine with sulfadoxine–pyrimethamine (SP).
Outcome Measures: Incidence of clinical and laboratory adverse events and rate of clinical
and/or parasitological failure at day 14 were recorded.
Results: The safety analysis population included 123 patients assigned to Cotrifazid, 123 to
mefloquine, and 123 to quinineþSP. The Cotrifazid group experienced lower overall incidence
of adverse events than the other groups. Among the efficacy analysis population (72 Cotrifazid,
71 mefloquine, and 75 quinine þ SP), clinical failure rate (symptoms and parasite load) on day
14 was equivalent for the three groups (0% for Cotrifazid and mefloquine; 1% for quinineþSP),
but parasitological failure rate (P. falciparum asexual blood-stage) was higher for Cotrifazid than
for mefloquine or quinine þ SP (9% [PCR corrected 8%] versus 0% and 3%, respectively [p ¼
0.02]).
Conclusion: Despite what appears to be short-term clinical equivalence, the notable
parasitological failure at day 14 in both P. falciparum and P. vivax makes Cotrifazid in its current
formulation and regimen a poor alternative combination therapy for malaria.
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PLoS CLINICAL TRIALSINTRODUCTION
Despite widespread efforts to prevent and treat malaria,
worldwide the burden of morbidity and mortality is still high,
due in part to the spread of drug-resistant Plasmodium spp.
strains. The increasing prevalence of strains of Plasmodium
falciparum resistant to 4-aminoquinolines and antifolate drugs
has created a crisis in the clinical treatment of malaria in
many countries, including Papua New Guinea (PNG) [1].
Introduced in 2001, the new ﬁrst-line treatment, amodia-
quine þ sulfadoxine–pyrimethamine (SP) for children weigh-
ing less than 20 kilograms or chloroquine þ SP for others, is
associated with up to 25% failure only two years after its
introduction (Marfurt et al., unpublished data). The need is
therefore urgent to ﬁnd and test alternative drugs.
Compounds already on the market for speciﬁc indications
can easily be screened for effects against neglected diseases.
Based on promising preliminary data, a ﬁxed combination
including cotrimoxazole, rifampicin, and isoniazid (Cotrifa-
zid) has been developed. It has the advantage of proven safety
and tolerability at higher dosage and for longer duration (in
tuberculosis).
The rationale to use this combination is based on animal
and human experiments. Rifampicin is active against P. berghei
malaria in rodents (Brun et al., unpublished data) [2]. In
humans, rifampicin showed partial efﬁcacy against P. vivax
when associated with primaquine [3]. Numerous studies have
shown cotrimoxazole to be active against malaria in humans
[4,5]. There is a pharmacokinetic synergism between cotri-
moxazole and rifampicin, with increased half-life and AUC
(area under the curve) when administered simultaneously [6].
Isoniazid has no clear antiplasmodial activity but delays
malaria mortality in mice and reduces overall parasite load
when given in combination with rifampicin and cotrimox-
azole (Brun et al., unpublished data).
Three studies on Cotrifazid have been conducted in
humans in endemic areas, including infants under 6 months
of age [7–9]. These studies showed Cotrifazid to be safe and
efﬁcacious for the treatment of falciparum malaria, whether
uncomplicated, complicated, or drug-resistant [9]. Never-
theless, a formal evaluation was deemed necessary, because
the scale of previous studies was small and their methodology
was ﬂawed. Additionally, the present study sought efﬁcacy
data in geographical areas other than Africa.
The objective of this trial was to compare, in patients with
chloroquine- or amodiaquine-resistant malaria, the efﬁcacy
and safety of Cotrifazid to that of meﬂoquine or quinineþSP.
The MRAC (Medical Research Advisory Committee) of Papua
New Guinea asked that the meﬂoquine arm be included, to
obtain in Papua New Guinean patients reliable safety and
efﬁcacy data on alternative drugs that had shown good
potential elsewhere.
METHODS
Participants
All patients older than 6 months of age presenting at the
centres (described below) who were diagnosed with malaria
(history of fever, OptiMAL test-positive, no other major
symptoms), and who had already been treated for malaria in
the 28 days before, qualiﬁed for inclusion in the study if the
individual or legal guardian (for children) gave informed
consent and if the clinician in charge would have given the
standard treatment for drug-resistant malaria independent of
the study. A participant was excluded if the clinician
preferred to use quinine þ SP for any reason (in case of
‘‘moderately severe’’ malaria), or if the patient had one of the
symptoms or signs of complicated or severe malaria (i.e.,
history of recent convulsion, any neurological sign or
impairment of consciousness, heavy vomiting, haemoglobi-
nuria, respiratory distress, bleeding, circulatory collapse,
shock, jaundice, or haemoglobin [Hb] ,5 g/dl), had contra-
indications for meﬂoquine (history of psychiatric disorder or
epilepsy), or was pregnant.
www.plosclinicaltrials.org December | 2006 | e38 0002
Cotrifazid against Malaria
Editorial Commentary
Background: In Papua New Guinea (PNG), malaria is an important cause
of death and disease in both adults and children. But concerns exist
about whether current antimalarial drugs will be viable for much longer,
indicating that new treatments are urgently needed. In 2001, new
recommendations on the first-line treatment for uncomplicated malaria
were introduced in PNG. These recommendations specify treating older
children and adults with the combination of chloroquine together with
sulfadoxine–pyrimethamine (SP). However, there is already evidence that
malaria parasites in PNG are evolving resistance to this combination
therapy. Therefore a group of researchers examined whether new
combinations of existing drugs for other diseases could be applied to
treatment of malaria in the region. They conducted a trial comparing
three different therapies in adults and children over the age of six
months who presented to primary care clinics with uncomplicated
malaria. The therapies compared were mefloquine (Lariam), quinine
taken together with SP, and Cotrifazid, a combination of three different
drugs mainly used against tuberculosis. Participants in the trial were
followed up for 14 days after treatment, and the main outcome the
researchers looked at was treatment failure (i.e., symptoms of clinical
malaria together with the presence of malaria parasites in the blood).
The researchers also compared the rate of adverse events and presence
of malaria parasites in the blood in the different treatment groups.
What the trial shows: Clinical treatment failure at day 14 was very low
(either 0% or close to 0%) and approximately equivalent in all three
treatment groups. The researchers then compared presence of malaria
parasites in the blood and found that a much higher proportion of
patients treated with Cotrifazid than the other two treatments had
parasites in the blood at day 14 (and the difference was statistically
significant). Overall the rate of adverse events was lower in the Cotrifazid
group than in the other two treatment groups.
Strengths and limitations: Studies like this one that examine novel
antimalarial treatments are particularly timely, as there is an urgent need
to find drugs that will treat malaria resistant to current therapies. In this
trial the procedures for randomizing participants to the different
treatments were appropriate. However, a key limitation is that patients
were followed up for only 14 days, and longer follow-up (as many groups
now recommend) might have allowed the researchers to more
accurately detect differences in efficacy between the treatments being
compared.
Contribution to the evidence: Few properly randomized controlled
trials have been conducted that look at the ability of Cotrifazid to treat
malaria. The results of the trial presented here suggest that Cotrifazid is
safe, and short-term clinical efficacy is approximately equivalent to
mefloquine or quinine plus SP. However, since in this trial Cotrifazid-
treated patients were more likely to have malaria parasites reappear in
the blood, Cotrifazid does not seem to be a good alternative treatment
in PNG.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.All patients suspected on clinical grounds to have drug-
resistant malaria were investigated by a nurse employed
speciﬁcally for the trial who performed the OptiMAL test
(Diamed, Cressier, Switzerland). If the latter was positive (any
Plasmodium species), patients were screened for other inclu-
sion and exclusion criteria and recruited when appropriate.
The patients were recruited in four primary care health
facilities: the outpatient clinic of Maprik hospital serving
Maprik District, the Kunjingini health subcentre serving the
Wosera area, the outpatient clinic of Yagaum hospital serving
the Amele community near Madang, and the Madang
outpatient clinic serving Madang town and its surroundings.
The Maprik and Wosera areas are situated in the East Sepik
Province and the Madang area is in the Madang Province,
PNG. Malaria transmission is intense and perennial in both
provinces, the Wosera being the most endemic with an overall
P. falciparum prevalence in the general population of 60%
[10,11]; in the Madang area, the falciparum prevalence is
about 40% [12,13].
Design
This was an open-label, block-randomised, comparative,
multicentric study. Patients were randomly assigned to
receive oral Cotrifazid, meﬂoquine, or quinine þ SP.
Interventions
Cotrifazid, a ﬁxed combination of rifampicin 112.5 mg,
sulfamethoxazole 200 mg þ trimethoprim 40 mg, and
isoniazid 75 mg (Fatol Arzneimittel GmbH, Schiffweiler,
Germany), was supplied as a coated tablet that could be
stored at room temperature. The treatment dosage and
schedule for patients was as follows. Patients weighing 40 kg
or more: two tablets twice per day; patients under 40 kg and
20 kg or more: one tablets twice per day; patients under 20 kg:
one-half tablet twice day. These doses were given every 12
hours for 7 days (days 0–6).
The treatment regimen for meﬂoquine (Lariam tablet
containing meﬂoquine 250 mg [F. Hoffmann-La-Roche Ltd,
Basel, Switzerland]) was given at the usual dosage of 25 mg/kg
in children, 1,250 mg for adults less than 60 kg, and 1,500 mg
for adults over 60 kg, split in two doses at hours 0 and 12.
Quinine (a commercial product in PNG) was given as usual:
10 mg/kg every 8 hours for 5 days (days 0–4). In this regimen,
patients also received a single dose of 0.5–3 tablets of
Fansidar (containing 500 mg of sulfadoxine and 25 mg of
pyrimethamine [F. Hoffmann-La-Roche Ltd, Basel, Switzer-
land]) on day 0.
The doses in the morning of days 0–3 were administered
under the supervision of the appointed nurses at the study
centres. They were responsible for conﬁrming both the
participant identiﬁcation number and the label of the trial
drugs. Intake of the afternoon doses on day 3 was checked by
interview on day 4, and intake of doses on days 4–6 by
interview on day 7.
Follow-up assessments were done on days 1, 2, and 3
(clinical and parasitological), 7 (clinical, parasitological, and
biochemical), and 14 (clinical, parasitological, and haemato-
logical), or more intensively in individual cases of persisting
symptoms or pathological signs. Blood samples were taken by
venipuncture (2 ml) on days 0 and 7 and by ﬁngerpick on days
1, 2, 3, and 14. For details on assessment procedures, see
‘‘Laboratory Procedures’’ below.
Treatment was changed to quinineþSP if the patient failed
treatment with other drugs. There was no rescue treatment if
the failure occurred after quinineþSP; a second course with
the same drugs was to be given, as stated in the national
guidelines at the time of the study.
Objectives
The speciﬁc objectives of the trial were (i) to compare the
efﬁcacy of Cotrifazid to that of the standard treatment for
drug-resistant malaria in PNG (quinine þ SP) and to another
drug (meﬂoquine) that is being considered for future use, and
(ii) to compare the tolerance of Cotrifazid with that of
quinine þ SP and meﬂoquine in the same population. The
trial was designed to test the null hypothesis that the clinical
cure rate with Cotrifazid is not inferior to that with the
comparators (meﬂoquine or quinine þ SP).
Outcomes
Safety parameters. The prime measurement of safety was
incidence of clinical or laboratory adverse events (AEs). All
patients were followed clinically every day for the ﬁrst four
days, and longer in cases of complication. All patients were
seen on days 7 and 14 to identify late AEs or clinical failure.
Laboratory measurements included serum glutamic-oxalo-
acetic transaminase (aspartate aminotransferase) (SGOT),
serum glutamate-pyruvate transaminase (alanine aminotrans-
ferase) (SGPT), and creatinine on days 0 and 7, and Hb
concentration on days 0 and 14.
AEs were deﬁned according to standard criteria, i.e., any
adverse change from the participant’s baseline (pretreat-
ment) condition (including clinically relevant laboratory
abnormalities, abnormal physical signs, and intercurrent
illnesses), irrespective of whether the event was considered
related to the trial drug or not. The occurrence of serious
AEs, as deﬁned by standard criteria, was recorded and acted
upon. There was no assessment of AE intensity or relatedness
to the product investigated because of the confounding effect
of malaria symptoms and signs.
Efﬁcacy parameters. The primary parameter of efﬁcacy was
the clinical treatment failure rate on day 14, using a blood
slide as gold standard for parasitology. Clinical treatment
failure was deﬁned as (i) the occurrence of severe malaria
between day 1 and day 14, or (ii) the persistence or
recurrence of symptoms or signs (including temperature
.37.5 8C) associated with any parasitaemia between day 5 and
day 14.
Secondary parameters of efﬁcacy were (i) parasitological
failure rate on day 14, (ii) fever clearance time, (iii) parasite
clearance time, (iv) symptom clearance time, (v) occurrence of
complications (information collected on days 1, 2, 3, 7 and 14)
and Hb concentration (from samples collected on day 14).
Sample Size
The overall sample size of 330 (110 in the Cotrifazid group,
110 in meﬂoquine, and 110 in quinine þ SP treatment) was
chosen to test the hypothesis that Cotrifazid was not inferior
to meﬂoquine or quinine þ SP, assuming a rate of treatment
success of 95% with meﬂoquine or quinine þ SP and a
clinically acceptable rate of treatment success of 86% or
more in the Cotrifazid group, and a 10% loss to follow-up
(80% power, 95% conﬁdence limits, one-sided test) [14].
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Assignment to treatment groups was done by a random-
isation list (block of 12, i.e., four Cotrifazid, four meﬂoquine,
and four quinine þ SP), which had been computer-generated
(SAS Software) by a statistician of the Swiss Tropical Institute
not involved in the study. The original list was kept at the
Swiss Tropical Institute and a copy at the PNG Institute of
Medical Research headquarters.
Randomisation—Allocation Concealment
Sequential numerical codes (1–390 to accommodate potential
errors at inclusion) were written on the reverse side of sealed
envelopes that had been prepared at the Swiss Tropical
Institute and forwarded to the local investigator prior to the
start of the study. Inside the envelope, the treatment group
was concealed on a paper with either the letter ‘‘L’’ for
Lariam (meﬂoquine), ‘‘C’’ for Cotrifazid, or ‘‘S’’ for standard
(quinine þ SP) written on it.
Randomisation—Implementation
Once a patient had met the inclusion criteria and his or her
(or the guardian’s) consent had been given, the patient was
assigned the code number following the one of the previous
patient. The envelope corresponding to that code number
was opened by the research nurse, and the ﬁrst dose of the
allocated treatment administered under supervision. The
entire process was to be completed before any procedure was
started for the following patient.
Blinding
This was an open-labelled trial. Neither the research nurse
nor the patients were blinded to the treatment given.
Laboratory Procedures
Parasitology. The OptiMAL test was used at screening (day
0) to document malaria.
On days 0, 1, 2, 3, 7, and 14 malarial parasites were assessed
by microscopy. Thick and thin ﬁlms were stained with Giemsa
at pH 7.2. Before a slide was declared negative 100 thick ﬁlm
ﬁelds were examined by microscopy. The number of malaria
parasites per 200 white blood cells was counted. The number
of asexual forms per ll was then calculated using a mean
white blood cell count of 10,000/ll in children below the age
of 5 y and of 8,000/ll in persons aged 5 y or older. The
standard quality control performed at the PNG Institute of
Medical Research was applied [11].
Haematology. Hb concentration was determined using a
photometer (Hemocue, Hemocue Ltd, Sweden).
Biochemistry. SGOT, SGPT, and creatinine were measured
with an automated dry chemical photometer (Reﬂotron
System, Boehringer-Mannheim, Mannheim, Germany). Regu-
lar quality controls were run for all the measurements.
Parasite genotyping. P. falciparum genotype proﬁles were
assessed on samples of day 0 and day of failure using a
combination of several molecular markers of the SP
resistance genes dhfr and dhps.
Ethics
The trial was approved by the Medical Research Advisory
Committee of PNG. Verbal informed consent from each
participant in the trial or from his/her parents or guardian(s)
was obtained in front of a witness after explanation of the
aims, methods, beneﬁts, and potential hazards of the trial.
Monitoring
A trial monitor (Isi Kevau, University of Papua New Guinea,
Port Moresby, Papua New Guinea) reviewed all procedures
and ensured complete adherence to the protocol.
Statistical Methods
Statistical methods. Data were double-entered using a
speciﬁc program written in FoxPro software version 3.0 and
analysed using Stata software version 8.2.
Safety. All participants who received at least one daily dose
of Cotrifazid or comparators and who presented to one
follow-up visit were included in the safety analysis popula-
tion. Comparisons of the incidence of AEs (following
prompted questions) reported at follow-up contacts (days
1–14) were performed using a Poisson model. Axillary
temperatures, respiratory rates, and Hb values are reported
as mean 6 standard deviation (SD).
Efﬁcacy. All participants who showed asexual parasites (any
species) at baseline and who received the treatment with
Cotrifazid, meﬂoquine, or quinine þ SP for at least the ﬁrst
three days (days 0–2), and who presented to the follow-up visit
on day 14, were included in the per protocol efﬁcacy analysis
population. Efﬁcacy was estimated by comparing the pro-
portions of complications and the rates of clinical and
parasitological failures between the Cotrifazid and compara-
tor groups, using the Mantel-Haenzel Chi-square test with a¼
0.05, one-tailed) or Fisher’s exact test where appropriate. A
Kaplan-Meier survival analysis of all asexual parasites, fever,
and symptoms was performed, and treatment groups com-
pared using the log rank test. The Student’s t-test was used to
compare means of Hb concentration between the groups.
An intention-to-treat analysis was also performed to assess
parasitological outcomes at day 14, counting all children who
didn’t appear for assessment on that day as failures.
RESULTS
Participant Flow and Number Analysed
The safety analysis population included 137 patients in the
Maprik hospital outpatient clinic, 49 in Kunjingini health
subcentre, and 183 in Madang town outpatient clinic. No
patient was admitted to the ward. The participant ﬂow is
detailed in Figure 1. A total of 369 patients were included,
using the OptiMAL test to detect parasitaemia: 123 in the
Cotrifazid group, 123 in the meﬂoquine group, and 123 in the
quinine þ SP group. Of the total in this group, 55 were
excluded on day 2 since they were found not to have been
treated with antimalarials in the last 28 days after reviewing
their health book (nonresistant malaria). Another 64 were
excluded because the microscopical investigation did not
conﬁrm the presence of asexual blood-stage parasites. The
lower detection of microscopy when compared to OptiMAL
is most likely due to the detection of circulating gametocytes
by the rapid test, a phenomenon that was not documented
when the study was designed and conducted.
In the efﬁcacy analysis population for the outcome
measures (clinical and parasitological failures on day 14), 32
patients were lost to follow-up on day 14, which left 218
patients (72 Cotrifazid, 71 meﬂoquine, and 75 quinine þ SP)
(see Figure 1).
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The study was conducted from April 2000 to January 2003.
Baseline Data
The female:male ratio was 180:184 (ﬁve were unknown). In
the Cotrifazid group the median age was 7.2 y (range 1.4–45
y), meﬂoquine 7.4 y (range 0.5–56 y), and quinine þ SP 8 y
(range 0.5–61 y).
The prevalence of reported symptoms and observed signs
at baseline for each treatment group is described in Table 1.
More patients had subjective and objective fever in the
quinine þ SP group: 45% (55/123) had a temperature over
37.5 8C at baseline versus 32% (39/123) for Cotrifazid and
34% (42/123) for meﬂoquine. Haematology values and
number of patients with abnormal liver and kidney function
tests at baseline are shown in Table 1. Elevated values of
SGOT were found in 26% of the Cotrifazid and quinineþSP
patients and 20% of the meﬂoquine patients.
Parasitology at baseline showed that 94% (80/85) of the
patients were infected with P. falciparum in the Cotrifazid
group, 90% (75/83) in the meﬂoquine group, and 87% (71/82)
in the quinine þ SP group. The corresponding values for P.
vivax were 8.2% (7/85), 9.6% (8/83), and 23% (19/83). A higher
prevalence of mixed infections was found in the quinineþSP
group (10% versus 4% in the Cotrifazid group and 4% in the
Figure 1. Participant Flow
doi:10.1371/journal.pctr.0010038.g001
www.plosclinicaltrials.org December | 2006 | e38 0005
Cotrifazid against Malariameﬂoquine group). Geometric mean densities were equiv-
alent.
Full compliance with the treatment evaluated from direct
observation in the ﬁrst three days and history-taking there-
after was 93% (115/123) in the Cotrifazid group (total of 7 d),
98% (121/123) in the meﬂoquine group (2 d), and 96% (118/
123) in the quinineþSP group (5 d). Two patients interrupted
their treatment due to AEs, both in the quinine þ SP group;
both were cured although none of them took an alternative
drug.
Outcome and Estimation: Adverse Events
No deaths occurred in this study. Among the 369 patients
included in the safety analysis, only one patient suffered from
a serious AE. This 1.7-y-old child, who was enrolled in the
Cotrifazid group, required hospital admission due to the
persistence of high fever, cough, and vomiting on day 3. The
child had 32,640 parasites/ll on day 0, 40 parasites/ll on day 2,
and none from day 3 onwards. Thus, the fever was very likely
of nonmalarial origin. The child was put on standard
treatment with quinine þ SP and antibiotics, and made a full
recovery. One child in the Cotrifazid and two in the
meﬂoquine group experienced an impairment of their level
of consciousness, but none was severe enough to warrant
rescue treatment with quinine þ SP or hospital admission.
One additional child developed chest indrawing during the
follow-up in the Cotrifazid group. In the Cotrifazid group,
four participants had yellow eye colour during follow-up
(days 1, 2, 3, and 7), but none in the other groups. The few
other non-prompted AEs—weakness in four patients, red
urine in three (all in the Cotrifazid group), sneezing in three,
facial swelling in one, and swollen lymph nodes in one—were
considered isolated events, and none required the admin-
istration of ancillary treatment.
The Cotrifazid group experienced a signiﬁcantly lower
overall incidence of prompted AEs during follow-up than the
other groups. Table 2 details the treatment-speciﬁc incidence
of these AEs recorded on days 1, 2, 3, 7, or 14, without
distinction between those related to the drug or to the
malaria episode. Vomiting was reported signiﬁcantly less
often in the Cotrifazid group than in the meﬂoquine group (p
, 0.001); stomach ache (p , 0.05), vomiting (p , 0.01),
dizziness (p , 0.05), and tinnitus (p , 0.01) were less common
in the Cotrifazid than in the quinineþSP group. In contrast,
participants in the Cotrifazid group were reported shortness
of breath signiﬁcantly more often than did those in the
meﬂoquine group (p , 0.01) (see Table 2 for details).
All abnormal biochemical tests observed at baseline (Table
1) had resolved by day 7, which was the only day of laboratory
follow-up for these values.
Outcome and Estimation: Efficacy
Clinical failure. Among the 218 patients retained in the
efﬁcacy analysis population, no patients developed signs of
severe malaria based on the clinician’s judgment, nor did any
require secondary hospital admission due to malaria. No
patients who were initially treated with Cotrifazid or
meﬂoquine required rescue treatment with quinine þ SP.
.......................................................................................................................................................................................
Table 1. Summary of Symptoms, Signs, and Laboratory Values by Treatment Group at Baseline
Category Characteristic Cotrifazid Mefloquine Quinine þ SP p-Values Overall
Symptoms Fever
a 81 (65.9) 85 (69.1) 99 (80.5) 0.03
Rigor/chills 37 (30.1) 47 (38.2) 48 (39.0) 0.27
Headache 56 (45.5) 64 (52.0) 63 (51.2) 0.54
Cough 34 (27.6) 38 (30.8) 40 (32.5) 0.70
Shortness of breath 2 (1.6) 3 (2.4) 2 (1.6) 1.00
b
Loss of appetite 48 (39.0) 45 (36.6) 44 (35.8) 0.91
Stomach ache 8 (6.5) 14 (11.4) 11 (8.9) 0.41
Vomiting 18 (14.6) 25 (20.3) 14 (11.4) 0.15
Diarrhoea 8 (6.5) 9 (7.3) 5 (4.1) 0.53
Dizziness 15 (12.2) 14 (11.4) 15 (12.2) 0.98
Itching 1 (0.8) 3 (2.4) 2 (1.6) 0.88
b
Loss of sleep 18 (14.6) 16 (13.0) 16 (13.0) 0.91
Paraesthesia 0 (0.0) 1 (0.8) 1 (0.8) 1.00
b
Tinnitus 1 (0.8) 1 (0.8) 0 (0.0) 1.00
b
Signs Temperature 37.2 8C 6 1.07 8C 37.2 8C 6 1.14 8C3 7 . 5 8C 6 1.17 8C 0.06
d
Temperature .37.5 8C
c 39 (31.7) 42 (34.1) 55 (44.7) 0.08
Respiratory rate, breaths/min 27.7 6 4.30 27.1 6 4.80 28.4 6 4.40 0.06
d
Enlarged spleen
e 38 (35.5) 41 (39.4) 41 (39.4) 0.90
Laboratory values
f SGOT (U/l) .33 (F) / 40 (M)
g 31 (26.1) 24 (20.2) 32 (26.2) 0.46
SGPT (U/l) .33 (F) / 40 (M)
g 10 (8.4) 11 (9.2) 6 (4.9) 0.87
Creatinine .100 lmol/l 3 (2.5) 3 (2.5) 1 (0.8) 0.58
b
Haemoglobin (g/dl) 9.54 6 2.10 9.37 6 2.02 9.52 6 1.77 0.77
d
All values are presented as n (%), except temperature, respiratory rate, and haemoglobin, which are given as mean 6 SD. Percentages are based on the safety population (n¼123 in
each group).
aFever ¼ Subjective feeling of fever.
bStatistical comparison done by Chi-square tests with Fisher’s exact test.
cAll patients were included who had increased temperature on day 0 or day 1.
dStatistical comparison done by Chi-square tests with ANOVA.
eThe percentages of enlarged spleen are based on the number of available data (n ¼ 107 in Cotrifazid, n ¼ 104 in mefloquine, and n ¼ 104 in quinine þ SP).
fPercentages of laboratory data are based on the number of available data points (n¼ 119 in Cotrifazid, n¼119 (SGOT, SGPT) and n¼118 (creatinine) in mefloquine, and n¼ 122 in
quinine þ SP).
g Thresold values for abnormality are different for females than for males
doi:10.1371/journal.pctr.0010038.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Cotrifazid against MalariaNo clinical treatment failures occurred with Cotrifazid or
meﬂoquine, but one late treatment failure (patient was
asymptomatic but had a temperature of 37.7 8C and parasite
density of 80/ll on day 14) occurred in the quinine þ SP
group. The three treatment groups were therefore equivalent
with regard to the clinical cure rate (100% in Cotrifazid and
meﬂoquine groups and 99% in quinine þ SP group, p ¼ 0.32,
Fisher’s exact test). However, due to the low sample size
ﬁnally included in the efﬁcacy analysis population, we had
only 80% power to ﬁnd a 4-fold increase in failure rate,
assuming a failure rate of 5% in the quinine þ SP group.
Parasitological failures. Parasitology results at baseline and
on day 1, 2, 3, 7, and 14 (per protocol analysis) are detailed in
Table 3.
When all patients sampled on a given day were taken into
account (irrespective of the other time points and species at
baseline), there was no difference in parasite clearance on day
1, 2, 3 and 7 (4% positive in all groups for the latter).
However, on day 14, the prevalence of asexual blood-stage
Plasmodium-positive patients was signiﬁcantly higher in the
Cotrifazid group at 15% (11/72) than in the meﬂoquine
group, 0% (0/71), and the quinine þ SP group at 4% (3/75)
(Fisher’s exact test, p ¼ 0.001). The rates for P. falciparum on
day 14 were 8% (6/72), 0% (0/71), and 3% (2/75) respectively (p
¼ 0.02, Fisher’s exact test).
When patients with P. falciparum only at baseline and
during follow-up were considered, 9% (6/67) had asexual
blood-stage parasitaemia on day 14 in the Cotrifazid group
versus 0% (0/63) in the meﬂoquine group and 3% (2/65) in the
quinine þ SP group (Fisher’s exact test, p ¼ 0.03). This
difference was not signiﬁcant when the Cotrifazid group was
compared to the quinine þ SP group (Table 3). Parasite
genotyping on individuals with reappearing P. falciparum
parasites showed that only 13% (1/8) of the failures were due
to new infections, which gives a PCR-corrected failure rate of
8% (versus 9% uncorrected). Patients in the Cotrifazid group
were more likely to develop P. falciparum gametocytaemia on
day 14 than those in the meﬂoquine or quinine þ SP groups:
38% (18/48) versus 5% (2/44) and 8% (4/53), respectively (p ,
0.001, Fisher’s exact test) (Table 3).
When patients with P. vivax only at baseline and during
follow-up were considered, the parasite prevalence on day 14
was 43% (3/7) in the Cotrifazid group, 0% (0/8) in the
meﬂoquine group, and 0% (0/15) in the quinineþSP group (p
¼ 0.01, Fisher’s exact test).
Intention-to-treat analysis did not lead to major changes
(see Table 4 for details). In fact, the prevalence of asexual
blood stage–positive patients (counting the missing ones as
positive) at day 14 was still signiﬁcantly higher in the
Cotrifazid group (28%) than in the meﬂoquine group (15%)
or the quinine þ SP group (12%) (p , 0.001, Fisher’s exact
test). The rates for P. falciparum were 22%, 15%, and 11%
respectively, and those for P. vivax 21%, 15%, and 10% (Table
4).
Survival analysis. The survival analyses are based only on
complete sequences of follow-up up to event occurrence.
Fever clearance time. Figure 2 shows the fever clearance
time in the three treatment groups. There was no signiﬁcant
difference between the groups treated with Cotrifazid,
meﬂoquine, or quinine þ SP.
Parasite clearance time. Figure 3 shows that the clearance
of all asexual parasites in the Cotrifazid group was slower
than in the other treatment groups, the difference with the
meﬂoquine group being signiﬁcant (p ¼ 0.01). There was also
a tendency for a slower clearance of P. falciparum in the
Cotrifazid group as compared to the other groups, but the
differences did not reach statistical signiﬁcance.
Haemoglobin concentration. The mean Hb concentrations
on day 14 were increased compared to the pretreatment
values on day 0: 10.4 6 1.9 (post-treatment) versus 9.54 6 2.1
g/dl (Cotrifazid group), 10.4 6 2.2 (post-treatment) versus
9.37 6 2.0 g/dl (meﬂoquine group), and 10.2 6 1.9 (post-
treatment) versus 9.52 6 1.8 g/dl (quinineþSP group). There
was no statistical difference between groups on day 0 (p ¼
0.77) or on day 14 (p ¼ 0.73).
DISCUSSION
Interpretation
The present study shows that Cotrifazid, a combination of
rifampicin, sulfamethoxazole, trimethoprim and isoniazid, is
safe and efﬁcacious for the alleviation of symptoms and signs
of drug-resistant malaria (clinical failure rate of 0% for
Cotrifazid and meﬂoquine, and 1% for quinine þ SP), but is
insufﬁcient to clear all parasites, especially those of P. vivax in
semi-immune Papua New Guinean populations.
Safety. The overall incidence of prompted AEs in the
C o t r i f a z i dg r o u pw a sl o w e rt h a nt h a to b s e r v e di nt h e
meﬂoquine and quinine þ SP groups. The types of AEs
recorded in these last two groups were consistent with those
of the literature, which also validates the data recorded for
Cotrifazid. Except for ‘‘shortness of breath,’’ none of the
prompted AEs was more frequent in the Cotrifazid group
.......................................................................................
Table 2. Summary of Incidences of AEs at Follow-Up (Days 1,
2, 3, 7, and 14) per 100 Contacts
Symptom Cotrifazid Mefloquine Quinine
þ SP
Overall
p-Values
a
Total number
of contacts
514 460 484 —
Fever
b 4.9 5.2 6.6 0.48
Rigor/Chills 1.4 1.5 2.5 0.38
Headache 6.3 3.3 7.9 0.01
Cough 6.0 4.8 5.2 0.69
Shortness of breath 1.2**
,c 0.0** 0.2
c 0.01
Loss of appetite 4.9 4.6 5.0 0.96
Stomach ache 1.0* 1.5 2.7* 0.11
Vomiting 0.4***
,** 3.0*** 2.7** 0.001
Diarrhoea 0.2 0.0 0.6 0.12
Dizziness 1.0
c,*2 . 4
c 2.9* 0.07
Itching 0.2 1.1 0.6 0.19
Loss of sleep 1.6 3.0 1.7 0.22
Paraesthesia 0.0 0.7 0.2 0.10
Tinnitus 0.4** 0.0 2.5** ,0.001
Incidence is defined as the number of contacts in which an AE was reported per 100
contacts. Cotrifazid group: 102 participants with five observations and one participant
with four observations; mefloquine group: 92 participants with five observations;
quinine þ SP: 96 participants with five observations and one participant with four
observations. All events were counted, whether or not a patient had the same event
already at baseline.
aSignificance levels for differences among all treatment groups following a Poisson
model.
bFever ¼ Subjective feeling of fever.
cPairwise difference not significant (p , 0.1)
Pairwise differences: *p , 0.05, **p , 0.01, ***p , 0.001.
doi:10.1371/journal.pctr.0010038.t002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Cotrifazid against Malaria(Table 2). The precise relatedness of the AEs to the drugs used
is not reported, since most AEs observed are also those that
are encountered during a malaria episode. The known
clinical and laboratory AEs of the components included in
the Cotrifazid combination were not observed, except for the
red-coloured urine—an AE that is not medically deleterious.
Efﬁcacy. Although the ﬁnal sample size for efﬁcacy analysis
was smaller than expected because the OptiMAL test used for
screening was positive in the presence of gametocytes only,
we were able to demonstrate equivalence of the three
regimens in curing uncomplicated malaria (primary out-
come). Indeed, all treatment groups had almost 0% clinical
failure, a rate that was lower than the 5% expected in the
sample size calculation. The short duration of our follow-up
is likely to have impacted positively on treatment outcome,
although it is not different from the one used in several
.......................................................................................................................................................................................
Table 4. Summary of Parasitological Results at Enrollment and Day 14: Intention-to-Treat Analysis
Timing Result Cotrifazid Mefloquine Quinine þ SP Overall p-Values
Baseline (days 0 or 1) Enrolled (OptiMAL test-positive), n 108 104 102 —
Microscopy positive for asexual species, n 85 83 82 0.95
Day 14 Not seen, n (%) 13 (15.3) 12 (14.5) 7 (8.5) 0.37
Asexual species positive (overall), n (%) 11(15.3) 0 (0.0) 3 (4.0) ,0.001
a,b
Positive or missing as per ITT, n (%) 24 (28.2) 12 (14.5) 10 (12.2) 0.02
b
Pf-positive or missing as per ITT, n (%) 19 (22.4) 12 (14.5) 9 (11.0) 0.12
a,d
Pv-positive or missing as per ITT, n (%) 18 (21.2) 12 (14.5) 8 (9.8) 0.12
a,e
All statistical comparisons were done by Chi-square or Fisher’s exact tests.
aCotrifazid versus quinine þ SP component: p ¼ 0.18, Chi-square (1) 1.8.
bCotrifazid versus quinine þ SP component: p ¼ 0.048, Fisher’s exact test.
cCotrifazid versus quinine þ SP component: p ¼ 0.01, Chi-square (1) 6.6.
dCotrifazid versus quinine þ SP component: p ¼ 0.05, Chi-square (1) 3.9.
eCotrifazid versus quinine þ SP component: p ¼ 0.04, Chi-square (1) 4.1.
ITT, intention-to-treat analysis
doi:10.1371/journal.pctr.0010038.t004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
.......................................................................................................................................................................................
Table 3. Summary of Parasitological Results at Enrolment and during Follow-Up (Days 1, 2, 3, 7 and 14): Per Protocol Analysis
Timing Characteristic Cotrifazid Mefloquine Quinine
þ SP
Overall
p-Values
Baseline
(days 0 or 1)
Enrolled (OptiMAL test-positive), n 108 104 102
Microscopy positive for asexual species, n 85 83 82 0.95
Pf-positive, n (%) 80 (94.1) 75 (90.4) 71 (86.6) 0.26
Pv-positive, n (%) 7 (8.2) 8 (9.6) 19 (23.2) 0.008
Pm-positive, n (%) 1 (1.2) 3 (3.6) 0 (0.0) 0.23
a
Mixed, n (%) 3 (3.5) Pf/Pv 2 (2.4) Pf/Pv; 1
(1.2) Pv/Pm
8 (9.8) Pf/Pv 0.16
a
Geometric mean density (asexual species combined) 7,147 7,864 9,750 0.56
Pf gametocytes, n (%) 28 (32.9) 25 (30.1) 18 (22.0) 0.26
Day 1 Slides collected, n 80 79 78
Asexual species positive (overall), n (%) 67 (83.8) 61 (77.2) 67 (85.9) 0.433
Day 2 Slides collected, n 76 75 70
Asexual species positive (overall), n (%) 26 (32.5) 16 (21.3) 25 (35.7) 0.11
Day 3 Slides collected, n 77 72 69
Asexual species positive (overall), n (%) 10 (13.0) 8 (11.1) 6 (8.7) 0.71
Day 7 Slides collected, n 70 71 70
Asexual species positive (overall), n (%) 3 (4.3) 3 (4.2) 3 (4.3) 0.99
a
Day 14
a Slides collected, n 72 71 75
Asexual species positive (overall), n (%) 11(15.3) 0 (0.0) 3 (4.0) 0.001
b
Pf-positive, n (%) 6 (8.3) 0 (0.0) 2 (2.7) 0.02
c
Pv-positive, n (%) 5 (6.9) 0 (0.0) 1 (1.3) 0.03
d
Pf-positive at baseline and Pf positive only day 14 6/67 (9.0) 0/63 (0.0) 2/65 (3.1) 0.03
e
Pf gametocyte negative at baseline and Pf gametocyte positive day 14 18/48 (37.5) 2/44 (4.5) 4/53 (7.5) ,0.001
f
Pv-positive at baseline and Pv positive only day 14 3/7 (42.9) 0/8 (0.0) 0/15 (0.0) 0.01
g
All statistical comparisons done by Chi-square or Fisher’s exact tests.
aFor the comparison of baseline and Day 14, only participants were considered in the denominator who had data at baseline (day 0 or day 1) and day 14.
bCotrifazid versus quinine þ SP component: p ¼ 0.046, Fisher’s exact test.
cCotrifazid versus quinine þ SP component: p ¼ 0.28, Fisher’s exact test.
dCotrifazid versus quinine þ SP component: p ¼ 0.21, Fisher’s exact test.
eCotrifazid versus quinine þ SP component: p ¼ 0.28, Fisher’s exact test.
fCotrifazid versus quinine þ SP component: p ¼ 0.001, Chi-square (1) 13.3.
gCotrifazid versus quinine þ SP component: p ¼ 0.023, Fisher’s exact test.
PF, P. falciparum; Pm, P. malariae; Pv, P. vivax.
doi:10.1371/journal.pctr.0010038.t003 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Cotrifazid against Malariarecent trials. A follow-up of 28–42 d, as proposed by White
[15] for long-acting drugs, would certainly have allowed us to
detect additional clinical failures, especially in the Cotrifazid
group in which 9% of the patients infected with P. falciparum
at baseline had recurrent parasites by microscopy on day 14.
At the time of study design (1999), we decided on a 14-day
follow-up since it was, and is still now, the standard duration
chosen to determine policy change in areas of intense
transmission [16]. Despite the short follow-up, we are still
able to compare our results with recent trials testing other
new drugs or regimens in Africa that also used 14 days for
assessing treatment outcome [17–24].
The situation is less promising when considering para-
sitological failures. Of the patients treated with Cotrifazid,
15% were parasitaemic (any Plasmodium species) on day 14
versus 4% for quinine þ SP and 0% for meﬂoquine. These
results reﬂect slower and less effective parasite clearance
(Figure 3) after Cotrifazid treatment, especially for P. vivax.
Most of the reappearing P. falciparum parasites (87%) were
true recrudescence, as expected with a follow-up of 14 days,
as well as from results of previous studies done in PNG [25,26]
Figure 2. Time to Fever Clearance: Kaplan-Meier Analysis
doi:10.1371/journal.pctr.0010038.g002
Figure 3. Time to Clearance of All Asexual Parasites: Kaplan-Meier Analysis
doi:10.1371/journal.pctr.0010038.g003
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and recent data from in vivo studies conducted in the same
area, where we found that only 6% (4/72) of the reappearing
parasites on day 14 were due to new infections (Marfurt et al.,
unpublished data). The situation is less clear for P. vivax, but a
recurrence is more likely than a new infection or relapse in a
time period of 14 days. Circulating asexual stages of P. vivax
after blood schizonticidal therapy might originate from
asexual parasites that survived therapy, from activated
hypnozoites that led to a relapse, or from a new infection.
Unlike with P. falciparum infections, in which true recrudes-
cence can be distinguished from new infections by the use of
genotyping methods, current molecular methods used for the
genetic analysis of P. vivax do not allow the unambiguous
classiﬁcation of recurrent parasitaemia, and hence of true
treatment failure.
Generalizability
The observation of no clinical treatment failure for Cotrifa-
zid but a signiﬁcant rate of parasitological failure is a matter
of great concern. In endemic areas, parasitological failure is
usually the ﬁrst sign of reduced activity of the drug used;
adequate clinical responses are still seen, despite persistent
parasitaemia, because host immunity helps to alleviate
symptoms [15]. The early parasitological failure rate, the
low efﬁcacy to suppress P. falciparum gametocytogenesis, and
the rather long regimen are the main reasons to conclude
that Cotrifazid is not an appropriate combination therapy,
especially in areas where both P. falciparum and P. vivax
infections coexist.
Overall Evidence
Three studies were conducted with Cotrifazid in the past, all
of rather small scale and one with serious methodological
ﬂaws (the randomisation was stopped at an early stage due to
the refusal of patients to be given the standard treatment
because of the perceived lower rate of adverse events and
excellent efﬁcacy of Cotrifazid) [7–9]. The present clinical
trial allowed Cotrifazid to be assessed in a large sample size of
patients, in an area where different Plasmodium species
coexist, and with effective drug regimens used as compara-
tors. Our results agree with previous ones, namely good safety
proﬁle and excellent efﬁcacy to alleviate symptoms. However,
Cotrifazid in our study was slightly less effective in clearing P.
falciparum parasites than in the African studies (8% failure
versus 5% respectively) [9]. Although small, this difference
might be due to the fact that parasites from PNG have
responded to different and more intense selective pressures
than those in Africa, and resemble more the Southeast Asian
parasites with a multidrug resistance proﬁle. This might be
especially so because we recruited only patients with 4-
aminoquinoline-resistant malaria; in the African study, this
group had 33% (2/6) parasitological failure. The conclusion of
the African study, ‘‘Cotrifazid is very well suited for the
treatment of malaria tropica, also in cases of apparent drug
resistance of P. falciparum against other antimalarials, and
even in severe cases of the disease’’ [9], does not, in our
opinion, accurately reﬂect their results, and is therefore
overoptimistic, especially in view of the tendency to only
consider a treatment acceptable if the overall failure is less
than 10%.
We believe that the design and power of our trial was
optimized to accurately assess Cotrifazid safety and efﬁcacy,
and the results therefore should robustly support any
conclusions on the usefulness of Cotrifazid as an antimalarial
drug. Despite its very good safety proﬁle, short-term clinical
equivalence with effective drugs such as meﬂoquine, and low
cost, Cotrifazid for malaria does not appear to be an ideal
alternative therapeutic option in its current formulation and
regimen: patients experience a slower parasite clearance,
some recurrence of asexual forms, and higher gametocytae-
mia on day 14 than after meﬂoquine or quinine þ SP
treatment. However, in formulating new and affordable
combinations of antimalarial drugs in the future, the clinical
efﬁcacy of the Cotrifazid components could be taken into
account, especially if it is considered an advantage, as part of
the Integrated Management of Childhood Illness strategy [27],
to use drugs that may act on both malaria and pneumonia.
SUPPORTING INFORMATION
CONSORT Checklist
Found at doi:10.1371/journal.pctr.0010038.sd001 (45 KB DOC).
Trial Protocol
Found at doi:10.1371/journal.pctr.0010038.sd002 (133 KB DOC).
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